Catalyst Wire Dossier Catalyst Wire Dossier

B/F/TAF FDC

bictegravir/emtricitabine/tenofovir alafenamide · Gilead Sciences
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for B/F/TAF FDC, covering 2019-12-05 to 2019-12-05. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years [Phase 3]

See pricing